← All trials
NCT05076617
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Oct 13, 2021
- Last posted
- Oct 13, 2021
- Enrollment
- 250
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.